The global apixaban market size was valued at USD 10.97 billion in 2025 and is projected to grow from USD 11.56 billion in 2026 to USD 17.64 billion by 2034, registering a CAGR of 5.42% during the forecast period (2026-2034). North America dominated the apixaban market with a share of 32.71% in 2025.
Apixaban is an oral anticoagulant that belongs to the direct factor Xa inhibitor class and works by blocking a key protein involved in blood clot formation. These medicines are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The apixaban market demand is driven by the need for effective oral anticoagulation, increasing diagnosis of atrial fibrillation, and the use of direct oral anticoagulants (DOAC). Healthcare providers prescribe branded and generic apixaban tablets in 2.5 mg and 5 mg strengths to support appropriate anticoagulation and reduce the risk of clot-related complications.
Download a Free Sample To learn more about this report,
Shift toward Generic Apixaban Formulations
The apixaban market analysis shows a shift towards generic apixaban formulations as patent expirations enable wider entry of lower-cost alternatives. Generic versions provide the same active ingredient as the branded drug and help improve affordability for patients requiring long-term anticoagulation. This trend is increasing price competition and expanding access to apixaban across healthcare systems.
Expansion of Apixaban Use in Venous Thromboembolism (VTE) Treatment
Apixaban is used for venous thromboembolism treatment, including deep vein thrombosis and pulmonary embolism. Its oral administration and predictable anticoagulant effects support its use for treating blood clots and preventing recurrence in eligible patients. This expansion is supporting demand across hospital and outpatient care settings.
Supply chain disruptions are expected to have a moderate impact on the apixaban market share due to dependence on active pharmaceutical ingredients, specialized chemicals, and formulation materials. The market is expected to follow a stair-step recovery, as delays in drug manufacturing and disruptions in pharmaceutical distribution can affect product availability. The market is expected to grow at a CAGR of 5.42%, but supply chain constraints could lower this by 0.8 percentage points, resulting in a growth of around 4.62%. As supply conditions normalize, the apixaban market growth is expected to gradually return to 5.42%.
The apixaban market forecasts strategic investment activity driven by expansion of direct-to-consumer pharmacy channels, improved access to branded anticoagulant therapies, and affordable prescription purchasing options. In April 2026, Bristol Myers Squibb and Pfizer expanded access to Eliquis through Mark Cuban Cost Plus Drug Company, offering a 30-day supply for USD 345 to eligible patients with prescriptions.
Demand for Stroke Prevention in Atrial Fibrillation and Need for Long Term Anticoagulation Therapy Drives Market
Demand for stroke prevention in atrial fibrillation is growing as this heart rhythm disorder increases the risk of blood clots and stroke. Apixaban helps reduce the risk of stroke and systemic embolism in eligible patients with atrial fibrillation. Its oral dosing and predictable anticoagulant effect make it a widely used treatment option. This need for effective stroke prevention is supporting growth of the apixaban market.
Need for long-term anticoagulation therapy is increasing as patients with conditions such as atrial fibrillation and venous thromboembolism may require ongoing protection against blood clots. Apixaban offers an oral treatment option for eligible patients and does not usually require routine coagulation monitoring. Its convenience for long-term use is supporting demand for apixaban.
Risk of Drug Interactions and Concerns About Reversal Agent Availability in Emergency Situations Restrain Market Expansion
Risk of drug interactions can create challenges in the use of apixaban, particularly among patients taking multiple medications. Certain drugs can affect apixaban levels in the body, potentially increasing bleeding risk or reducing its anticoagulant effect. These interactions may require treatment adjustments and careful review of a patient's medication history.
Concerns about reversal agent availability in emergency situations can affect confidence in apixaban treatment. In cases of severe or life-threatening bleeding, healthcare providers may need rapid access to appropriate reversal treatment and emergency care facilities. Limited availability or high costs of reversal agents can create additional challenges for hospitals and patients.
Expansion of Apixaban Supply Through Online Pharmacy Platforms and Outpatient Anticoagulation Management Offers Growth Opportunities
Pharmaceutical manufacturers and distributors can partner with licensed online pharmacies to improve the availability of apixaban through digital prescription fulfillment and home delivery services. These platforms can help patients access prescribed medicines conveniently while enabling pharmacies to serve a wider customer base. Revenue can be generated through digital pharmacy partnerships, distribution agreements, and recurring medicine supply contracts, contributing to apixaban market growth.
Healthcare providers and pharmaceutical distributors can develop supply and care arrangements with outpatient clinics that manage patients requiring ongoing anticoagulation. Regular prescription reviews, medication monitoring, and coordinated pharmacy services can support continuity of care under medical supervision.
2.5 mg is anticipated to record a CAGR of 5.78% during the forecast period, fueled by its use in stroke prevention for eligible patients with atrial fibrillation and in reducing the risk of recurrent blood clots in appropriate patient groups.
The 5 mg segment is expected to achieve a CAGR of 5.19% during the forecast period, shaped by its established use in preventing stroke and systemic embolism in eligible patients with atrial fibrillation and treating venous thromboembolism.
Request Customizationto receive a tailored report.
Atrial fibrillation dominated the indication segment in 2025, accounting for a share of 56.4%, owing to the widespread need for anticoagulation therapy to reduce the risk of stroke and systemic embolism among eligible patients.
Pulmonary embolism is projected to register a CAGR of 5.89% during the forecast period, supported by the need for effective anticoagulation to treat blood clots in the lungs and reduce the risk of recurrence.
Drug stores & retail pharmacies dominated the distribution channel segment in 2025, accounting for a share of 45.8%, reflecting their accessibility and role in dispensing prescribed anticoagulant medications for ongoing treatment.
The Online Pharmacies segment is likely to witness a CAGR of 7.02% during the forecast period, propelled by the adoption of online prescription services, home delivery, and convenient access to recurring medications.
Speak to an Analystto discuss market opportunities.
The North America apixaban market accounted for a dominant share of 32.71% in 2025.
U.S. market benefits from the ARISTOTLE clinical trial, which demonstrated the efficacy of apixaban in reducing stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation compared with warfarin. These findings strengthened the clinical evidence supporting apixaban as a Factor Xa inhibitor and contributed to its established role among prescription anticoagulant drugs.
Canadian Cardiovascular Society’s atrial fibrillation guidelines recommends direct oral anticoagulants for eligible patients requiring stroke prevention. Apixaban’s role in these treatment recommendations supports its use as an oral Factor Xa inhibitor and strengthens demand for anticoagulant drugs in routine cardiovascular care.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific apixaban market is expected to grow at a CAGR of 7.13% during the forecast period, making it the fastest-growing region.
India’s market is supported by the availability of Eliquis and generic apixaban formulations for treating deep vein thrombosis (DVT) and pulmonary embolism and preventing recurrent blood clots. The availability of different tablet strengths supports treatment planning for acute venous thromboembolism and extended thrombosis prevention, strengthening demand for oral anticoagulant therapy.
China’s National Healthcare Security Administration’s annual reimbursement list updates influence access to covered medicines, supporting the broader anticoagulant treatment landscape for conditions such as deep vein thrombosis (DVT) and pulmonary embolism. This creates opportunities for apixaban and other anticoagulant drugs used in thrombosis prevention, subject to local approval and reimbursement status.
Japanese Circulation Society guidelines for pulmonary embolism and deep vein thrombosis recognizes apixaban as a direct oral anticoagulant for treating venous thromboembolism. The updated recommendations address anticoagulation duration and recurrence prevention, supporting demand for apixaban in deep vein thrombosis (DVT), pulmonary embolism, and thrombosis prevention.
The Europe apixaban market is estimated to grow at a CAGR of 5.18% during the forecast period.
Germany’s market is supported by the availability of generic apixaban formulations following patent expiry, which has increased competition and expanded access to anticoagulant therapy. Generic versions marketed by pharmaceutical companies provide additional options for patients requiring long term medication, strengthening demand for generic anticoagulants.
UK market is driven by NHS prescribing guidance and cost effective anticoagulant use. The National Institute for Health and Care Excellence (NICE) recommends apixaban as an option for stroke prevention in eligible patients with atrial fibrillation, supporting its use within routine cardiovascular care and strengthening demand for generic anticoagulants and pharmaceutical therapeutics.
The Latin America apixaban market is projected to grow at a CAGR of 5.73% during the forecast period. Brazilian Thoracic Association’s clinical guidelines for pulmonary embolism, published in the Jornal Brasileiro de Pneumologia. The guidelines evaluate direct oral anticoagulants, including apixaban, for patients with stable pulmonary embolism.
Mexico's COFEPRIS authorized a bioequivalence study of Asofarma de México’s apixaban 5 mg tablets against Eliquis, providing a specific example of generic product development and regulatory evaluation. Such developments can expand treatment options and competition among medicines used for pulmonary embolism management and thrombosis prevention.
Middle East & Africa's apixaban market is expected to grow at a CAGR of 5.96% during the forecast period. In the UAE, the apixaban market is supported by the Emirates Cardiac Society’s efforts to improve atrial fibrillation diagnosis and management.
South African Heart Association’s guidance on managing atrial fibrillation and clinical use of direct oral anticoagulants in eligible patients supports demand for apixaban as part of cardiovascular drug care, particularly for long-term blood clot prevention.
The apixaban market competitive landscape is highly fragmented, with anticoagulant drug developers, generic medicine producers, and specialty pharmaceutical companies. Key players such as Bristol-Myers Squibb Company, Pfizer Inc., Viatris Inc., Centaur Pharmaceuticals Pvt. Ltd., and Sandoz Group AG are estimated to account for 35–40% of the global apixaban market share.
Established players compete mainly through branded & generic apixaban formulations, product quality, regulatory compliance, and manufacturing capacity. Emerging and regional players in the apixaban market ecosystem focus on cost-effective generic formulations, regional market expansion, and broader access to anticoagulant therapies.
September 2026: Lupin Limited received tentative US FDA approval for apixaban oral suspension at 1.25 mg/mL through the 505(b)(2) regulatory pathway.
April 2026: Dr. Reddy’s Laboratories received Australian registration for generic apixaban.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Congenital Hyperinsulinism Treatment Market Size, Opportunities, 2034
Acute Kidney Injury Treatment Market Size, Forecast, Demand, 2034
Clinical Trial Packaging Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Cryptococcosis Market Size, Forecast, Demand, Opportunities, 2034
Asbestosis Treatment Market Size, Forecast, Demand, 2034
We are featured on:
sales@straitsresearch.com